Can we better predict which skin cancers will spread?
NCT ID NCT05695222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 1,500 people with a common skin cancer called cutaneous squamous cell carcinoma. Most cases are cured with surgery, but a small number can spread and become dangerous. Researchers will compare current staging systems to see which best predicts poor outcomes, aiming to improve future patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients treated at two tertiary Dermatology centers
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Over 18 years old with diagnosis of CSCC Exclusion Criteria: * Patients who decline for their data to be used for research purposes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cutaneous squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dr Emilia Peleva
ACTIVE_NOT_RECRUITINGLondon, United Kingdom
-
Whipps Cross University Hospital
RECRUITINGLondon, E11 1NR, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy before surgery may cut skin cancer recurrence
- Scientists map metabolic shifts in skin cancer development
- Cancer-Killing virus shows promise in early trial for advanced tumors
- New drug IDP-001 takes on advanced cancers in early trial
- New combo therapy aims to shrink inoperable skin cancers
- Tiny needle patch takes aim at skin cancer